Gluten Technology and Education for Celiac Health
Key facts
- Where
- Boston, Chicago, Nashville, and New York, United StatesSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06059716, who can take part
Where in United States
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Jocelyn Silvester, MD, PhDTaking people
- University of Chicago Medical CenterChicago, United StatesContact: Sonia Kupfer, MDTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Dawn Adams, MDTaking people
- Columbia University Irving Medical CenterNew York, United StatesContact: Benjamin Lebwohl, MD, MSTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Columbia University
- Trial code
- NCT06059716
- Record updated
- 10 June 2026
- Original description
The investigators propose to plan for a multi-center randomized controlled trial (M-RCT) to test the effectiveness of novel gluten detection technologies as an adjunct to telemedicine to manage celiac disease in newly diagnosed adults. If successful, the proposed intervention will improve mucosal recovery, promote a shift in current practice of celiac disease management toward long-term monitoring, and represent a significant step toward reducing the severe physical and psychological consequences of celiac disease.Read full original descriptionShow less
The investigators propose to plan for a multi-center randomized controlled trial (M-RCT) to test the effectiveness of novel gluten detection technologies as an adjunct to telemedicine to manage celiac disease in newly diagnosed adults. If successful, the proposed intervention will improve mucosal recovery, promote a shift in current practice of celiac disease management toward long-term monitoring, and represent a significant step toward reducing the severe physical and psychological consequences of celiac disease.
Inclusion: Any gender; Age 18-75 years; Celiac disease diagnosis by serology and duodenal biopsy (corresponding to •Marsh 3 histology), adequate sampling and interpretable villus height to crypt depth ratio upon review by our study pathologist; Diagnosed with celiac disease within 4 months of initial study screening; Willingness to use gluten-detection technology; Not currently using a gluten detection technology that tests for gluten in urine or stool.
Exclusion: Concurrent participation in a clinical trial of an experimental pharmacologic agent (for any condition); Currently pregnant or planning to become pregnant during the study; Not planning to follow a gluten-free diet.